<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369250</url>
  </required_header>
  <id_info>
    <org_study_id>GDCRI/ACM/PG/PhD/12/2013-14</org_study_id>
    <nct_id>NCT02369250</nct_id>
  </id_info>
  <brief_title>Rosuvastatin Gel With 1:1 Mixture of Platelet-rich Fibrin and Bone Graft in Mandibular Degree II Furcation Defects</brief_title>
  <official_title>Rosuvastatin 1.2mg in Situ Gel Combined With 1:1 Mixture of Autologous Platelet-rich Fibrin and Porus- Hydroxyappatite Bone Graft in Surgical Treatment of Mandibular Degree II Furcation Defects: A Randomized Clinical Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Government Dental College and Research Institute, Bangalore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Government Dental College and Research Institute, Bangalore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rosuvastatin (RSV) is a new synthetic, second-generation, sulfur-containing, hydrophilic&#xD;
      statin, that stimulate bone formation in critical-size cortical bone defects adjacent to&#xD;
      titanium implants, when administered locally in bone. Platelet-rich fibrin (PRF) is a&#xD;
      platelet concentrate with sustained release of various growth factors, having regenerative&#xD;
      potential to treat periodontal defects. Porous hydroxyapatite (HA) bone grafting material has&#xD;
      clinically satisfactory response, when used to fill periodontal intrabony defects. This&#xD;
      double-masked randomized study is designed to evaluate the potency of combination of RSV&#xD;
      1.2mg in situ gel with 1:1 mixture of autologous PRF and HA bone graft in the surgical&#xD;
      treatment of mandibular degree II furcation defects when compared with autologous PRF and HA&#xD;
      bone graft placed after open flap debridement (OFD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABSTRACT Background: A wide range of regenerative materials have been tried in the treatment&#xD;
      of furcation defects. Rosuvastatin (RSV) is a new synthetic, second-generation,&#xD;
      sulfur-containing, hydrophilic statin, that stimulate bone formation in critical-size&#xD;
      cortical bone defects adjacent to titanium implants, when administered locally in bone.&#xD;
      Platelet-rich fibrin (PRF) is a platelet concentrate with sustained release of various growth&#xD;
      factors, having regenerative potential to treat periodontal defects. Porous hydroxyapatite&#xD;
      (HA) bone grafting material has clinically satisfactory response, when used to fill&#xD;
      periodontal intrabony defects. This double-masked randomized study is designed to evaluate&#xD;
      the potency of combination of RSV 1.2mg in situ gel with 1:1 mixture of autologous PRF and HA&#xD;
      bone graft in the surgical treatment of mandibular degree II furcation defects when compared&#xD;
      with autologous PRF and HA bone graft placed after open flap debridement (OFD).&#xD;
&#xD;
      Material and methods 105 patients with mandibular buccal Class II furcation defects were&#xD;
      randomly allotted and treated either with, OFD and placebo gel: Group 1, or OFD + autologous&#xD;
      PRF and porus-HA bone graft: Group 2, or OFD + RSV 1.2mg in situ gel combined with autologous&#xD;
      PRF and porus-HA bone graft: Group 3. Clinical parameters were recorded at baseline before&#xD;
      SRP and at 9 months; they included modified sulcus bleeding index (mSBI), probing depth (PD),&#xD;
      and relative vertical (RVAL) and horizontal (RHAL) attachment levels. At baseline and after 9&#xD;
      months, radiographic assessment of bone defect fill was performed postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BONE FILL</measure>
    <time_frame>9 MONTHS</time_frame>
    <description>BONE FILL/ defect depth reduction recorded at baseline and at 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probing depth</measure>
    <time_frame>9 months</time_frame>
    <description>Probing depth recorded at baselin and at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical attachment level</measure>
    <time_frame>9 months</time_frame>
    <description>Gain in Clinical attachment level from cementoenamel junction to the base of the periodontal pocket</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Furcation Defects</condition>
  <arm_group>
    <arm_group_label>OFD+ PLACEBO GEL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>furcation defect site is surgically debrid and placed a placebo gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OFD+ PRF + BONE GRAFT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following surgical debridment of furcation site autologous PRF and bone graft is placed in defect as a competator drug used is platelet rich fibrin and porus hydroxyapatite bone graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV1.2% gel + PRF+ BG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following surgical debridment of furcation site Rosuvastatin 1.2% in situ gel combined with autologous PRF and bone graft is placed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin, is a statin group of drug.</description>
    <arm_group_label>RSV1.2% gel + PRF+ BG</arm_group_label>
    <other_name>statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platelet rich fibrin</intervention_name>
    <description>AUTOLOGUS PLATELET GROWTH FACTOR</description>
    <arm_group_label>OFD+ PRF + BONE GRAFT</arm_group_label>
    <other_name>platelet concentrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. the presence of buccal Class II furcation defects in endodontically vital,&#xD;
             asymptomatic mandibular first and second molars with a radiolucency in the furcation&#xD;
             area on an intraoral periapical radiograph with PD ± 5mm and horizontal PD ± 3mm after&#xD;
             Phase I therapy (SRP)&#xD;
&#xD;
          2. no history of antibiotic or periodontal therapy in the preceding 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. systemic illness known to affect the outcomes of periodontal therapy, such as diabetes&#xD;
             mellitus, cardiac diseases, insufficient platelet count (&lt;200,000/mm3), or&#xD;
             immunocompromised (e.g., HIV individuals) patients taking medications, such as&#xD;
             corticosteroids or calcium channel blockers, which are known to interfere with&#xD;
             periodontal wound healing&#xD;
&#xD;
          2. individuals known or suspected allergy to the RSV group or allergic to medications&#xD;
&#xD;
          3. systemic statin therapy&#xD;
&#xD;
          4. pregnant or lactating women&#xD;
&#xD;
          5. patients using tobacco in any form&#xD;
&#xD;
          6. individuals with unacceptable oral hygiene (plaque index &gt;1.5). In addition, teeth&#xD;
             with interproximal intrabony defects, gingival recession, endodontic (pulpal)&#xD;
             involvement, or mobility of tooth ≥ Grade II were also excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>February 17, 2015</last_update_submitted>
  <last_update_submitted_qc>February 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Government Dental College and Research Institute, Bangalore</investigator_affiliation>
    <investigator_full_name>Dr. A R Pradeep</investigator_full_name>
    <investigator_title>Proffesor and Head, dept of periodontology</investigator_title>
  </responsible_party>
  <keyword>regeneration</keyword>
  <keyword>surgical therapy</keyword>
  <keyword>furcation defect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furcation Defects</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

